Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

by Zacks Equity Research

Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

    Here's Why Investors Should Buy Integra LifeSciences Now

    by Zacks Equity Research

    The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

      TransEnterix Senhance Surgical Robotic System Wins FDA Nod

      by Zacks Equity Research

      TransEnterix (TRXC) works on expanding in robotic surgery consistently.

        Abbott Banks on FDA Approvals and Buyouts, Competition Rife

        by Zacks Equity Research

        The market is upbeat about Abbott's (ABT) latest initiatives.

          MedTech Players Eyeing Emerging Market Growth Opportunities

          by Zacks Equity Research

          The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.

            DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

            by Zacks Equity Research

            DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

              Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders

              by Zacks Equity Research

              Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.

                QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

                by Zacks Equity Research

                The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

                  Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business

                  by Zacks Equity Research

                  Express Scripts (ESRX) is consistently trying to expand its core PBM business.

                    Is a Beat in Store for Abbott (ABT) This Earnings Season?

                    by Zacks Equity Research

                    Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

                      Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

                      by Zacks Equity Research

                      With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

                        QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

                        by Zacks Equity Research

                        QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

                          Illumina (ILMN) Strong on Product Launches, Competition Rife

                          by Zacks Equity Research

                          Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.

                            Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                            by Zacks Equity Research

                            The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.

                              Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

                              by Zacks Equity Research

                              Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

                                Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm

                                by Zacks Equity Research

                                Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.

                                  Abbott's Ellipse ICD Receives FDA Approval for MRI Scans

                                  by Zacks Equity Research

                                  Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.

                                    Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm

                                    by Zacks Equity Research

                                    Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.

                                      Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI

                                      by Zacks Equity Research

                                      Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.

                                        Abiomed's Latest Regulatory Progress Boosts Impella Line

                                        by Zacks Equity Research

                                        We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.

                                          Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                          by Zacks Equity Research

                                          The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

                                            Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod

                                            by Zacks Equity Research

                                            Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.

                                              4 Top MedTech Stocks for Dividend Investors in 2017

                                              by Zacks Equity Research

                                              Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks.

                                                Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                                                by Zacks Equity Research

                                                Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.

                                                  Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

                                                  by Zacks Equity Research

                                                  The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.